New markers of bone and collagen turnover in children and adults with growth hormone deficiency
- PMID: 8290428
- PMCID: PMC2399931
- DOI: 10.1136/pgmj.69.817.846
New markers of bone and collagen turnover in children and adults with growth hormone deficiency
Abstract
Serum bone Gla protein (BGP), a marker of osteoblastic function, serum carboxyterminal cross-linked telopeptide of type I collagen (ICTP), a marker of bone resorption, and serum aminoterminal propeptide of type III procollagen (PIIINP) levels, an index of collagen synthesis, were determined in seven children and eight adults with congenital growth hormone deficiency (GHD). In children with GHD, serum BGP (mean +/- s.e.: 12.9 +/- 0.7 ng/ml), ICTP (8.3 +/- 1.3 ng/ml) and PIINP (3.5 +/- 0.5 ng/ml) levels were significantly lower (P < 0.001) than those recorded in normal children (BGP 18.9 +/- 0.8 ng/ml, ICTP 14.4 +/- 0.5 ng/ml and PIIINP 6.7 +/- 0.7 ng/ml). Total alkaline phosphatase (184.7 +/- 13.4 IU/l) and bone alkaline phosphatase (77.8 +/- 4.1 IU/l) levels were also significantly lower (P < 0.0001) than in controls (338.1 +/- 14.9 IU/l and 181.0 +/- 7.8 IU/l, respectively). Serum BGP, ICTP and PIIINP levels were not significantly correlated with height velocity values. In adults with GHD, mean BGP levels (3.8 +/- 0.3 ng/ml) were significantly lower (P < 0.0001) than those recorded in normals (5.4 +/- 0.1 ng/ml). On the contrary, serum ICTP levels were similar to those found in controls (patients: 4.7 +/- 0.8 ng/ml vs normals: 4.1 +/- 0.3 ng/ml), suggesting the presence of a normal resorption activity associated with a reduced osteoblastic function. This finding was also confirmed by the presence of reduced bone alkaline phosphatase levels (GHD: 44.9 +/- 6.9 IU/I vs controls: 58.3 +/- 2.0 IU/I; P<0.02), while the less specific total alkaline phosphatase levels (119.5 +/- 14.8 IU/I) were similar to those recorded in normal subjects (122.3 +/- 4.0 IU/I). Serum PIIINP levels (3.7 +/- 0.6 ng/ml) were similar to those recorded in normals (3.2 +/- 0.2 ng/ml), suggesting that in adulthood the collagen turnover is not negatively influenced by the chronic GHD. No significant correlations were found between BGP/ICTP/PIIINP and IGF-I levels. In conclusion, our data show that in children with GHD the lack of GH insulin-like growth factor-I (IGF-I) effects on bone and collagen turnover is associated with a significant reduction of bone turnover (low bone formation plus low bone resoRption) and collagen synthesis. On the contrary, adult GHD seems to exert less relevant effects on bone and collagen turnover, probably due to the fact that in adult life further hormones or local factors might partially counteract the negative consequences of chronic GH-IGF-I deficiency.
Similar articles
-
Growth hormone treatment in adults with GH deficiency: effects on new biochemical markers of bone and collagen turnover.J Endocrinol Invest. 1993 Dec;16(11):893-8. doi: 10.1007/BF03348952. J Endocrinol Invest. 1993. PMID: 8144866
-
[Effect of GH/IGF-I deficiency on bone and collagen turnover in children and adults with GH deficiency].Minerva Endocrinol. 1995 Jun;20(2):135-40. Minerva Endocrinol. 1995. PMID: 8531895 Italian.
-
Dose-dependent effects of recombinant human growth hormone on biochemical markers of bone and collagen metabolism in adult growth hormone deficiency.Eur J Endocrinol. 1996 Dec;135(6):666-71. doi: 10.1530/eje.0.1350666. Eur J Endocrinol. 1996. PMID: 9025710
-
Biochemical markers of bone turnover.Horm Res. 1996;45 Suppl 1:55-8. doi: 10.1159/000184832. Horm Res. 1996. PMID: 8805033 Review.
-
Biochemical markers of bone collagen type I metabolism.Ukr Biochem J. 2015 Jan-Feb;87(1):21-32. doi: 10.15407/ubj87.01.021. Ukr Biochem J. 2015. PMID: 26036128 Review.
Cited by
-
Modifications of biochemical markers of bone and collagen turnover during corticosteroid therapy.J Endocrinol Invest. 1996 Feb;19(2):127-30. doi: 10.1007/BF03349848. J Endocrinol Invest. 1996. PMID: 8778165
-
Growth hormone treatment in adults with GH deficiency: effects on new biochemical markers of bone and collagen turnover.J Endocrinol Invest. 1993 Dec;16(11):893-8. doi: 10.1007/BF03348952. J Endocrinol Invest. 1993. PMID: 8144866
-
Long-term monitoring of rec-GH treatment by serial determination of serum aminoterminal propeptide of type III procollagen in children and adults with GH deficiency.J Endocrinol Invest. 1999 Mar;22(3):169-75. doi: 10.1007/BF03343537. J Endocrinol Invest. 1999. PMID: 10219883 Clinical Trial.
-
Effects of 12 months rec-GH therapy on bone and collagen turnover and bone mineral density in GH deficient children with thalassaemia major.J Endocrinol Invest. 2000 Jun;23(6):356-61. doi: 10.1007/BF03343738. J Endocrinol Invest. 2000. PMID: 10908162
-
Effects of 12-month GH treatment on bone metabolism and bone mineral density in adults with adult-onset GH deficiency.J Endocrinol Invest. 2001 Apr;24(4):224-30. doi: 10.1007/BF03343851. J Endocrinol Invest. 2001. PMID: 11383908
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous